568PPersonalized medicine in individuals living with late onset Pompe disease (LOPD): urine glucose tetrasaccharide (Glc4) as a predictive biomarker during follow-up.
Saved in:
| Title: | 568PPersonalized medicine in individuals living with late onset Pompe disease (LOPD): urine glucose tetrasaccharide (Glc4) as a predictive biomarker during follow-up. |
|---|---|
| Authors: | Lessard, L.1 (AUTHOR), Chitimus, D.2,3,4 (AUTHOR), Froissart, R.5 (AUTHOR), Bouhour, F.6,7,8 (AUTHOR), Hamroun, D.9 (AUTHOR), Laforêt, P.3 (AUTHOR), Pettazzoni, M.5 (AUTHOR) |
| Source: | Neuromuscular Disorders. 2025 Supplement, Vol. 53, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09608966 |
|---|---|
| DOI: | 10.1016/j.nmd.2025.106124 |
